Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H M Kvasnicka

Showing results (101-110 of 110) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 110 results.
The Journal of Pathology|March 1, 1997
Apoptosis and proliferation (PCNA labelling) in CML--a comparative immunohistological study on bone marrow biopsies following interferon and busulfan therapyJ Thiele, T K Zirbes, J Lorenzen, et al.
Annals of Hematology|March 1, 1995
The impact of interferon versus busulfan therapy on the reticulin stain-measured fibrosis in CML--a comparative morphometric study on sequential trephine biopsiesJ Thiele, H M Kvasnicka, N Niederle, et al.
Hematopathology and Molecular Hematology|January 1, 1996
Effects of interferon treatment on the macrophage population in the bone marrow of patients with Ph1+-CMLJ Thiele, H M Kvasnicka, T K Zirbes, et al.
Histology and Histopathology|September 18, 2004
Effects of the tyrosine kinase inhibitor imatinib mesylate (STI571) on bone marrow features in patients with chronic myelogenous leukemiaJ Thiele, H M Kvasnicka, A Schmitt-Graeff, et al.
Der Pathologe|June 5, 2004
[Regression of the Philadelphia chromosome (bcr/abl)-positive myelo- and megakaryopoiesis after Imatinib (STI571) therapy in chronic myelogenous leukemia (CML)]J Thiele, H M Kvasnicka, E Varus, et al.
Histology and Histopathology|June 10, 2005
Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantationJ Thiele, H M Kvasnicka, H Dietrich, et al.
Histopathology|April 22, 2005
Bone marrow changes in chronic myelogenous leukaemia after long-term treatment with the tyrosine kinase inhibitor STI571: an immunohistochemical study on 75 patientsJ Thiele, H M Kvasnicka, A Schmitt-Graeff, et al.
Leukemia & Lymphoma|February 16, 2000
Bone marrow features and clinical findings in chronic myeloid leukemia--a comparative, multicenter, immunohistological and morphometric study on 614 patientsJ Thiele, H M Kvasnicka, A Schmitt-Graeff, et al.
Acta Neuropathologica Communications|March 2, 2018
CD74 regulates complexity of tumor cell HLA class II peptidome in brain metastasis and is a positive prognostic marker for patient survivalP S Zeiner, J Zinke, D J Kowalewski, et al.
The Netherlands Journal of Medicine|March 18, 1999
Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosisJ J Michiels, J Kutti, P Stark, et al.
Pageof 11

Showing results (101-110 of 110) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 110 results.
The Journal of Pathology|March 1, 1997
Apoptosis and proliferation (PCNA labelling) in CML--a comparative immunohistological study on bone marrow biopsies following interferon and busulfan therapyJ Thiele, T K Zirbes, J Lorenzen, et al.
Annals of Hematology|March 1, 1995
The impact of interferon versus busulfan therapy on the reticulin stain-measured fibrosis in CML--a comparative morphometric study on sequential trephine biopsiesJ Thiele, H M Kvasnicka, N Niederle, et al.
Hematopathology and Molecular Hematology|January 1, 1996
Effects of interferon treatment on the macrophage population in the bone marrow of patients with Ph1+-CMLJ Thiele, H M Kvasnicka, T K Zirbes, et al.
Histology and Histopathology|September 18, 2004
Effects of the tyrosine kinase inhibitor imatinib mesylate (STI571) on bone marrow features in patients with chronic myelogenous leukemiaJ Thiele, H M Kvasnicka, A Schmitt-Graeff, et al.
Der Pathologe|June 5, 2004
[Regression of the Philadelphia chromosome (bcr/abl)-positive myelo- and megakaryopoiesis after Imatinib (STI571) therapy in chronic myelogenous leukemia (CML)]J Thiele, H M Kvasnicka, E Varus, et al.
Histology and Histopathology|June 10, 2005
Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantationJ Thiele, H M Kvasnicka, H Dietrich, et al.
Histopathology|April 22, 2005
Bone marrow changes in chronic myelogenous leukaemia after long-term treatment with the tyrosine kinase inhibitor STI571: an immunohistochemical study on 75 patientsJ Thiele, H M Kvasnicka, A Schmitt-Graeff, et al.
Leukemia & Lymphoma|February 16, 2000
Bone marrow features and clinical findings in chronic myeloid leukemia--a comparative, multicenter, immunohistological and morphometric study on 614 patientsJ Thiele, H M Kvasnicka, A Schmitt-Graeff, et al.
Acta Neuropathologica Communications|March 2, 2018
CD74 regulates complexity of tumor cell HLA class II peptidome in brain metastasis and is a positive prognostic marker for patient survivalP S Zeiner, J Zinke, D J Kowalewski, et al.
The Netherlands Journal of Medicine|March 18, 1999
Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosisJ J Michiels, J Kutti, P Stark, et al.
Pageof 11